Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

The drug had already failed in two phase 3 trials in 2012 – but Lilly pressed on with a third trial in mild Alzheimer’s after spotting a trend in the data suggesting an effect in a small group ...

Lilly said Friday that it hopes discussions about the drug continue with the agency ... that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.

The EU medicines regulator on Friday rejected Eli Lilly's (LLY.N), opens new tab Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

European Committee Says Lilly Alzheimer's Drug Shouldn't Get Marketing Approval A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over ...

that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit. Shares of Eli Lilly ...